•  
  •  
  •  
  •  

2025-10-26 01:43:20

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • GPT Infraprojects Ltd receives order worth Rs. 195 crore
  • Acknit Industries Ltd to close operations at Unit 1 in Falta Special Economic Zone
  • Bhagyanagar India Ltd Q2FY26 consolidated PAT higher at Rs. 11.27 crores
  • Zen Technologies Ltd Q2 FY2025-26 consolidated profit increases QoQ to Rs. 59.39 crores
  • Seshasayee Paper and Boards Ltd consolidated Q2FY26 PAT up QoQ at Rs. 22.41 crores

Keywords Selected:  Release

Stock Report

  • Nisus Finance's Promoter Announces Release of Pledged Shares & Company pairing down its Loan Obligation
  • Zinema Media and Entertainment Ltd updates on release of Blackmail
  • Vrusshabha roars into Cinemas on November 6, 2025
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended Release Tablets USP, 25 mg and 37.5 mg.
  • Zinema Media and Entertainment Ltd to release tamil film BLACKMAIL
  • Lupin receives U.S. FDA approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg, and 400 mg
  • Gas Release Incident at ONGC Rudrasagar Field: Situation Under Control
  • Vrusshabha Releasing in Cinemas on October 16, 2025
  • Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg
  • Pritish Nandy Communications and Netflix announce the release of The Royals, on May 9
  • ZIM Laboratories Ltd receives Marketing Authorization for Dimethyl Fumarate (120 mg & 240 mg) Modified Release Capsules in Portugal, Europe
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg
  • Granules India Ltd announces ANDA Approval for Bupropion Hydrochloride Extended-Release Tablets
  • Zydus receives final approval from USFDA for Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg
  • GV Films announces the Long-Awaited Release of 'The White Land'
  • Alembic Pharmaceuticals announces USFDA Final Approval for Lamotrigine ExtendedRelease Tablets USP, 200 mg, 250 mg, and 300 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Paliperidone Extended Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg
  • Ramco Systems announces the launch of Aviation Software 6.0 for smarter aircraft management
  • Lupin Launches Mirabegron Extended-Release Tablets in the United States
  • Zydus receives final approval from USFDA for Amantadine extended-release capsules 68.5 mg and tentative approval for 137 mg
  • Zydus receives tentative approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg - OTC

Latest Post

  • GPT Infraprojects Ltd receives order worth Rs. 195 crore
  • Acknit Industries Ltd to close operations at Unit 1 in Falta Special Economic Zone
  • Bhagyanagar India Ltd Q2FY26 consolidated PAT higher at Rs. 11.27 crores
  • Zen Technologies Ltd Q2 FY2025-26 consolidated profit increases QoQ to Rs. 59.39 crores
  • Seshasayee Paper and Boards Ltd consolidated Q2FY26 PAT up QoQ at Rs. 22.41 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024